Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Adalimumab · Abrilada, Amjevita

Monoclonal antibody · Antagonist of tumor necrosis factor-alpha (TNF) · developed by Abbvie

Approved FDA, Dec 2002
ABBV Developer
3 Registered trials

What is Adalimumab?

Adalimumab is an approved antibody studied in Rheumatoid Arthritis, Plaque Psoriasis, Healthy Volunteers.

At a glance

Also known as
Abrilada, Amjevita, Cyltezo, Yuflyma, CHS-1420, AVT02
Drug type
Monoclonal antibody
Targets
tumor necrosis factor-alpha (TNF)
Mechanism
Antagonist of tumor necrosis factor-alpha (TNF)
Pathways
TNF-mediated inflammatory and immune responses, leukocyte migration via adhesion molecules (ELAM-1, VCAM-1, ICAM-1)
Therapy area
Immunology, Musculoskeletal
Developer
Abbvie Inc (ABBV)
Also in trials of
ALVO, CHRS
FDA status
Approved as Abrilada, Amjevita, Cyltezo (December 31, 2002), BLA125057 · FDA label

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02489227 Phase 3 Plaque Psoriasis Completed CHRS
NCT06972446 Phase 2 Rheumatoid Arthritis Recruiting ABBV
NCT03579823 Phase 1 Healthy Volunteers Completed ALVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Rheumatoid ArthritisHealthy VolunteersPlaque Psoriasis

Other drugs acting on TNF

Golimumab FDA approved

More from Abbvie

Atogepant FDA approved Pivekimab Sunirine FDA approved Risankizumab FDA approved Telisotuzumab Vedotin FDA approved Upadacitinib FDA approved Venetoclax FDA approved ABBV-1042 Phase 1 ABBV-291 Phase 1 ABBV-295 Phase 2 ABBV-313 Phase 1 ABBV-324 Phase 1 ABBV-438 Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind Adalimumab

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.